In the GIST clinical trial, 7 (5%) patients experienced CTC grade 3/ 4 GI bleeds (3 patients), intra-tumoural bleeds (3 patients) or both (1 patient).
GIST kliinilises uuringus täheldati kokku seitsmel patsiendil (5%) III/ IV astme